Publications by authors named "M E Melisko"
The NCCN Guidelines for Survivorship include recommendations for screening, evaluation, and treatment of psychosocial and physical problems resulting from adult-onset cancer and its treatment. They also include recommendations to promote healthy behaviors and immunizations in survivors and provide a framework for care coordination. These NCCN Guidelines Insights summarize the panel's current recommendations regarding sexual health and fertility.
View Article and Find Full Text PDFBackground: Cancer-related cognitive impairment (CRCI) is reported by 45% of patients with cancer. Significant gaps in knowledge remain regarding the mechanisms that underlie CRCI.
Objectives: Using a data-driven approach, the study purpose was to evaluate for perturbed pathways associated with membership in the High versus the Low CRCI profiles.
Article Synopsis
- - The study aimed to understand MRI imaging patterns in breast cancer patients undergoing neoadjuvant immunotherapy, particularly focusing on responses to various combinations of chemotherapy and immunotherapy in the I-SPY2 clinical trial.
- - Out of 43 patients analyzed, 44.4% receiving the chemo-immunotherapy experienced increased lymphadenopathy in the first 12 weeks, significantly higher compared to just 6.3% in the control group, with most cases linked to the SD-101 and pembrolizumab treatment.
- - Despite observing increased lymphadenopathy in some patients, this was not associated with a higher incidence of positive lymph nodes at surgery, even as breast tumor sizes decreased over time.
Objectives: We describe the development and implementation of a system for monitoring patient-reported adverse events and quality of life using electronic Patient Reported Outcome (ePRO) instruments in the I-SPY2 Trial, a phase II clinical trial for locally advanced breast cancer. We describe the administration of technological, workflow, and behavior change interventions and their associated impact on questionnaire completion.
Materials And Methods: Using the OpenClinica electronic data capture system, we developed rules-based logic to build automated ePRO surveys, customized to the I-SPY2 treatment schedule.
Background: Treatment options for human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases (BCBMs) remain limited. We previously reported central nervous system (CNS) activity for neratinib and neratinib-capecitabine. Preclinical data suggest that neratinib may overcome resistance to ado-trastuzumab emtansine (T-DM1) when given in combination.
View Article and Find Full Text PDF